TSANZ Abstracts

Abstract

Introduction/Aim: Idiopathic pulmonary fibrosis (IPF) constitutes largest component of the fibrotic interstitial lung diseases (ILD) and further research is warranted to improve patient care. We describe the clinical characteristics of patients with IPF from the Australasian Interstitial Lung Disease Registry (AILDR) in 2022. Methods: The AILDR is a bi-national ILD database established in 2016, which incorporates prospective epidemiological and investigational data from centres across Australasia. We investigated the baseline demographics and characteristics of current IPF cohort enrolled between May 2016 and September 2022. Results: 731 IPF patients from a total of 2680 AILDR participants across 16 centres were included, with New South Wales constituting the largest proportion at 44.9%. The study cohort was male predominant (n = 538, 73.6%), had mean age 73.98.5 years and mean BMI 29.35.0 kg/m2, with 432 (67.5%) participants being ever-smokers. Ethnicity identified 543 (90.5%) participants as Caucasian, 19 (3.17%) participants respectively for Asian, Indian and others. At baseline, this cohort had mean FVC of 81.018.2% and mean D L CO of 60.519.1%. 55 (7.5%) participants reported a family history of pulmonary fibrosis. The three commonest comorbidities were cardiac disease (n = 260, 37.5%), previous surgery (n = 170, 24.6%) and gastro-oesophageal reflux disease (n = 152, 20.8%). New South Wales has the highest percentage of IPF patients across Australia and New Zealand (n = 328,44.9%). With regards to IPF treatment, 334 (45.7%) participants were on antifibrotics (nintedanib: n = 197 [59%]; pirfenidone: n = 210 [63%]). and 74 (10.1%) participants were on immunomodulators. Conclusion: The AILDR IPF cohort provides useful clinical information in the approach to standardise IPF management across Australasia.